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Background: Type 2 diabetes mellitus has been associated with an excess risk of 
colorectal cancer, although the time–risk relationship is unclear, and there is limited 
information on the role of antidiabetic medications.
aim: We examined the association between type 2 diabetes, antidiabetic medications, 
and the risk of colorectal cancer, considering also duration of exposures.
Methods: We analyzed data derived from two companion case–control studies con-
ducted in Italy and Spain between 2007 and 2013 on 1,147 histologically confirmed 
colorectal cancer cases and 1,594 corresponding controls. Odds ratios (ORs) and 95% 
confidence intervals (CIs) were estimated by unconditional multiple logistic regression 
models, adjusted for socioeconomic factors and major potential confounding factors.
results: Overall, 14% of cases and 12% of controls reported a diagnosis of diabetes, cor-
responding to an OR of colorectal cancer of 1.21 (95% CI 0.95–1.55). The OR was 1.49 
(95% CI 0.97–2.29) for a duration of diabetes of at least 15 years. The OR was 1.53 (95% 
CI 1.06–2.19) for proximal colon cancer, 0.94 (95% CI 0.66–1.36) for distal colon cancer, 
and 1.32 (95% CI 0.94–1.87) for rectal cancer. In comparison with no use, metformin use 
was associated with a decreased colorectal cancer risk (OR 0.47, 95% CI 0.24–0.92), 
while insulin use was associated with an increased risk (OR 2.20, 95% CI 1.12–4.33); 
these associations were stronger for longer use (OR 0.36 and 8.18 for ≥10 years of use of 
metformin and insulin, respectively).
conclusion: This study shows evidence of a positive association between diabetes and 
colorectal cancer, mainly proximal colon cancer. Moreover, it indicates a negative associa-
tion between colorectal cancer and metformin use and a positive association for insulin use.
Keywords: antidiabetic medications, colorectal cancer, diabetes, insulin, metformin, risk factor
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inTrODUcTiOn
Colorectal cancer is the third most common cancer and the 
fourth leading cause of cancer death worldwide, and the fourth 
and second, respectively, in Europe (1, 2). Among established 
risk factors for this neoplasm are high consumption of red and 
processed meat, heavy alcohol consumption, body fatness, and 
family history of colorectal cancer, whereas physical activity, 
regular aspirin use, statin use, and, probably, a diet rich in fiber, 
especially from fruit and vegetables, appear to have a protective 
role against this neoplasm (3–6).
Type 2 diabetes mellitus has been associated with an excess risk 
of colorectal cancer (7–10), as well as with of cancers related to 
metabolic factors (11, 12). Although the magnitude of the excess 
risk appears to be modest (about 30%), it may have important 
public health implications given the high prevalence of diabetes. 
The association has been found to be consistent between study 
designs (i.e., cohort versus case–control studies), sex, and cancer 
subtypes (i.e., colon versus rectum) (7, 9, 13, 14). However, only 
a few studies considered the timing of the disease in relation to 
colorectal cancer diagnosis, reporting no clear trend in risk (9).
Diabetes medications have also been associated with colorec-
tal cancer risk in some studies which suggested that insulin use 
may increase the risk (15), while metformin (15–17) and thiazo-
lidinedione (15, 18) use may reduce it. The evidence on diabetes 
medications is, however, still inconsistent, and only scanty studies 
considered time–risk relationships (15).
We further examined the association between type 2 diabetes, 
antidiabetic medications, and colorectal cancer risk using data 
from two companion case–control studies from Italy and Spain, 
where information on duration of exposures was considered.
MaTerials anD MeThODs
study Population
The present data derive from the HIWATE Project (19, 20), which 
includes two companion case–control studies conducted in Italy 
and Spain between September 2007 and December 2013. The 
first was conducted in Northern Italy (Milan and Pordenone/
Udine areas) between 2008 and 2010 on 456 colorectal cancer 
cases (median age 67, range 35–80) and 569 controls (median 
age 66, range 31–80  years); the latter was conducted in Spain 
(Barcelona area) between 2007 and 2013 on 696 colorectal cancer 
cases (median age 68, range 22–85) and 1,036 controls (median 
age 66, range 28–85  years). Patients with no information on 
diabetes history (two cases and six controls), with a diagnosis of 
type 1 diabetes (one case and one control from Italy), or with a 
diagnosis of diabetes before age 30 (two cases and four controls) 
were excluded from the present analyses, thus leaving a total of 
1,147 cases and 1,594 controls, 455 and 567 from Italy and 692 
and 1,027 from Spain, respectively.
In both studies, cases were incident, histologically confirmed 
colorectal cancer patients, admitted to reference study centers 
in the study areas. Three hundred nine cases had a diagnosis of 
proximal colon cancer (i.e., cecum, International Classification 
of Diseases, vol. 10, ICD 10  =  C18.0, ascending colon, ICD 
10 = C18.2, hepatic flexure, ICD 10 = C18.3, or transverse colon, 
ICD 10 = C18.4), 415 of distal colon cancer (i.e., splenic flexure, 
ICD 10 = C18.5, descending colon, ICD 10 = C18.6, or sigmoid 
colon, ICD 10 = C18.7), 16 of overlapping colon cancer or not oth-
erwise specified colon (NOS) cancer, ICD 10 = C18.8 and C18.9, 
397 of rectal cancer (i.e., rectosigmoid junction, ICD 10 = C19.9, 
or rectum, ICD 10 =  C20.9) and for 10 cases the anatomical 
subsite was not indicated. In Italy, controls were patients admit-
ted to the same hospitals as cases for a wide spectrum of acute, 
non-neoplastic conditions unrelated to factors likely related to 
colorectal cancer. In Spain, controls were population-based and 
were identified from the lists of selected family practitioners and 
contacted by telephone. Cases and controls were resident in the 
enrollment areas for at least 6 months prior to diagnosis (cases) 
or recruitment (controls). The study protocols were approved by 
the ethical review boards of the participating centers, and all par-
ticipants signed an informed consent form before recruitment. 
Average response rates among patients approached were 95% in 
Italy and 68% in Spain, among cases, and 95% in Italy and 53% in 
Spain, among controls.
All patients were interviewed by ad  hoc trained interview-
ers using similar structured questionnaires to collect personal 
information on sociodemographic factors, lifestyle habits (e.g., 
tobacco smoking, alcohol drinking, physical activity, and dietary 
habits), anthropometric measures, a problem-oriented medical 
history, and family history of cancer. In both studies, history of 
diabetes was self-reported and included the age at first diagnosis. 
In the Spanish study, additional information on antidiabetic 
medications was collected, including use of oral antidiabetic 
drugs and insulin, and corresponding duration. Only patients 
with treated diabetes and a diagnosis of diabetes more than 
1 year before cancer diagnosis/interview were considered among 
diabetic patients.
statistical analysis
To assess the association between diabetes and diabetes-related 
variables and colorectal cancer risk, we used unconditional 
logistic regression to estimate the odds ratios (ORs) and cor-
responding 95% confidence intervals (CIs) adjusted for soci-
odemographic factors (i.e., study center, sex, age, and education) 
and major potential confounding factors, i.e., tobacco smoking, 
alcohol drinking, body mass index, lifetime leisure physical activ-
ity, statin use, and regular aspirin use. Further adjustment for 
consumption of meat, fruit, and vegetables and for total energy 
intake was also considered. In sensitivity analyses, we provided 
the OR for patients with a diagnosis of diabetes more than 2 or 
more years (or 3 or more years) prior to cancer diagnosis.
To assess the association between colorectal cancer and 
antidiabetic medications, we selected diabetic patients only. 
Therefore, the risk of colorectal cancer for diabetic patients using 
a specific antidiabetic drug was compared with that of diabetic 
patients using other antidiabetic medications. Alternatively, we 
considered as reference category diabetic patients using other 
antidiabetic medications plus non-diabetic patients.
We used additional models to assess the potential modifying 
effect of selected covariates on the association with diabetes and 
colorectal cancer risk, and we tested for heterogeneity across 
strata of the covariates (i.e., multiplicative interaction) using 
TaBle 1 | Distribution of 1,147 colorectal cancer cases and 1,594 
controls, according to sex, age, and other selected characteristics.
characteristics cases controls p-Valuea
N % N %
study center
Milan, Italy 238 20.7 247 15.5
Pordenone/Udine, Italy 217 18.9 320 20.1
Barcelona, Spain 692 60.3 1,027 64.4 0.002
sex
Men 750 65.4 998 62.6
Women 397 34.6 596 37.4 0.14
age
<60 259 22.6 428 26.9
60–64 179 15.6 266 16.7
65–69 236 20.6 318 19.9
70–74 211 18.4 293 18.4
≥75 262 22.8 289 18.1 0.0008
education (years)
<8 676 58.9 790 49.6
8–12 286 24.9 456 28.6
≥13 183 16.0 347 21.8 <0.0001
Missing 2 0.2 1 0.1
Tobacco smoking
Never smokers 459 40.0 664 41.7
Former smokers 467 40.7 618 38.8
Current 214 18.7 310 19.4 0.53
Missing 7 0.6 2 0.1
alcohol consumption (drinks/day)
0 271 23.6 265 16.6
>0 to <1 274 23.9 535 33.6
1 to <4 359 31.3 517 32.4
≥4 183 16.0 160 10.0 0.43
Missing 60 5.2 117 7.3
Body mass index (kg/m2)
<25 399 34.8 544 34.1
25 to <30 505 44.0 706 44.3
≥30 242 21.1 340 21.3 0.76
Missing 1 0.1 4 0.3
Physical activity (MeTs h/week)
0 287 25.0 362 22.7
>0 to 8 388 33.8 546 34.3
>8 472 41.2 648 40.7 0.46
Missing 0 0 38 2.4
statin use
Never 909 79.3 1,144 71.8
Ever 233 20.3 448 28.1 <0.0001
Missing 5 0.4 2 0.1
regular aspirin use
Never 977 85.2 1,336 83.8
Ever 157 13.7 250 15.7 0.15
Missing 13 1.1 8 0.5
Italy and Spain, 2007–2013.
METS, metabolic equivalents of task.
ap-Values calculated from χ2 statistics (χ2 for trend for ordinal variables).
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likelihood ratio tests and the resulting χ2 statistics. All statistical 
analyses were performed with SAS 9.2 statistical software (SAS 
Institute, Cary, NC, USA).
resUlTs
Table 1 gives the distribution of colorectal cancer cases and con-
trols, according to selected characteristics. Cases and controls had 
a similar distribution by sex, tobacco smoking, alcohol drinking, 
body mass index, leisure-time physical activity, and regular aspi-
rin use. Cases were somewhat older and heavier alcohol drinkers, 
and reported a lower level of education, and a lower use of statins 
than controls.
The distribution of colorectal cancer cases and controls by 
history of diabetes and the corresponding ORs by country and 
overall are shown in Table 2. Overall, 159 (13.9%) of cases and 
188 (11.8%) of controls reported a diagnosis of type 2 diabetes, 
corresponding to a multivariable OR of 1.21 (95% CI 0.95–1.55). 
The OR was 1.12 in the Italian study and 1.20 in the Spanish study. 
The OR of colorectal cancer was higher for a duration of diabetes 
of ≥15 years (OR 1.49, 95% CI 0.97–2.29), but the trend in risk 
for increasing duration was not significant (p-value  =  0.10). 
Corresponding values were 1.68 in Italy and 1.47 in Spain. In sen-
sitivities analyses excluding patients with a diagnosis of diabetes 
within 2 or 3 years prior to cancer diagnosis, the OR were 1.16 
(95% CI 0.89–1.50) and 1.15 (95% CI 0.88–1.50), respectively, in 
the two studies combined (data not shown). Further allowance 
for selected dietary factors (e.g., meat, fruit or vegetables) or total 
energy intake did not meaningfully change our risk estimates 
(data not shown).
No significant heterogeneity was observed in risk estimates 
across strata of sex, age, education, tobacco smoking, alcohol 
consumption, body mass index, physical activity, and statin and 
aspirin use (Table S1 in Supplementary Material).
Table  3 shows the distribution of anatomical subsites of 
colorectal cancer cases and corresponding controls, and the OR 
estimates according to history of diabetes by country and overall. 
In both countries combined, the OR was 1.15 (95% CI 0.89–1.55) 
for colon cancer overall, 1.53 (95% CI 1.06–2.19) for proximal 
colon, 0.94 (95% CI 0.66–1.36) for distal colon, and 1.32 (95% CI 
0.94–1.87) for rectal cancer. Corresponding estimates were 1.04, 
1.32, 0.94, and 1.46 in Italy and 1.15, 1.64, 0.88, 1.27 in Spain. The 
OR for overlapping and NOS colon cancer was not shown due to 
the limited number of patients.
Table  4 shows the distribution of colorectal cancer cases 
and controls, and the corresponding ORs, according to use of 
antidiabetic medications in diabetic patients from the Spanish 
study. Diabetic patients using any oral antidiabetic drug had a 
non-significant reduced risk of colorectal cancer as compared to 
those not using them (OR 0.59, 95% CI 0.18–1.92). The OR was 
significantly below unity in diabetic patients using metformin 
(OR 0.47, 95% CI 0.24–0.92) as compared with those not using 
it, with a trend of decreasing risk with increasing duration of use 
(OR 0.36, 95% CI 0.15–0.85, for ≥10  years of use; p-value for 
trend 0.005). Among other oral antidiabetic drugs, sulfonylurea 
derivatives were not significantly associated with colorectal 
cancer risk (OR 1.14, 95% CI 0.63–2.10). Diabetic patients using 
insulin had an increased risk of colorectal cancer as compared 
with those not using it (OR 2.20, 95% CI 1.12–4.33); the OR 
increased with increasing duration of insulin use and was 8.18 
(95% CI 2.06–32.50) for ≥10 years of use (p-value for trend 0.002). 
TaBle 3 | Distribution of anatomical subsites of colorectal cancera cases and corresponding controls, with odds ratios (Ors) and 95% confidence 
intervals (cis), according to history of diabetes by country and overall.
history of diabetes italy spain Overall
cases/controls Orb (95% ci) cases/controls Orb (95% ci) cases/controls Orb (95% ci)
Overall colon cancersa
No 274/520 1.00c 365/886 1.00c 639/1,406 1.00c
Yes 26/47 1.04 (0.61–1.76) 75/141 1.15 (0.82–1.63) 101/188 1.15 (0.89–1.55)
Proximal colon cancers
No 109/520 1.00c 147/886 1.00c 256/1,406 1.00c
Yes 13/47 1.32 (0.67–2.62) 40/141 1.64 (1.05–2.56) 53/188 1.53 (1.06–2.19)
Distal colon cancers
No 150/520 1.00c 218/886 1.00c 368/1,406 1.00c
Yes 12/47 0.94 (0.46–1.88) 35/141 0.88 (0.57–1.36) 47/188 0.94 (0.66–1.36)
rectal cancers
No 140/520 1.00c 200/886 1.00c 340/1,406 1.00c
Yes 15/47 1.46 (0.74–2.85) 42/141 1.27 (0.84–1.93) 57/188 1.32 (0.94–1.87)
Italy and Spain, 2007–2013.
aThese include proximal colon, distal colon, and overlapping or not otherwise specified colon cancers.
bEstimates from multiple logistic regression models including terms for study center, sex, age, education, tobacco smoking, alcohol drinking, body mass index, physical activity, statin 
use, and aspirin use.
cReference category, no history of diabetes.
TaBle 2 | Distribution of 1,147 colorectal cancer cases and corresponding 1,594 controls, with odds ratios (Ors) and 95% confidence intervals (cis), 
according to history of diabetes by country and overall.
italy spain Overall
cases  
N (%)
controls  
N (%)
Ora  
(95% ci)
cases  
N (%)
controls  
N (%)
Ora  
(95% ci)
cases  
N (%)
controls  
N (%)
Ora  
(95% ci)
history of diabetes
No 414 (91.0) 520 (91.7) 1.00b 574 (82.9) 886 (86.3) 1.00b 988 (86.1) 1,406 (88.2) 1.00b
Yes 41 (9.0) 47 (8.3) 1.12 (0.70–1.78) 118 (17.1) 141 (13.7) 1.20 (0.89–1.62) 159 (13.9)    188 (11.8) 1.21 (0.95–1.55)
Duration of diabetes (years)
1 to <5 11 (26.8) 14 (29.8) 1.05 (0.45–2.45) 32 (27.1) 34 (24.1) 1.31 (0.77–2.24) 43 (27.0)      48 (25.5) 1.21 (0.78–1.88)
5 to <10 7 (17.1) 7 (14.9) 1.18 (0.39–3.57) 22 (18.6) 39 (27.7) 0.85 (0.48–1.50) 29 (18.2)      46 (24.5) 0.96 (0.59–1.57)
10 to <15 6 (14.6) 13 (27.7) 0.58 (0.21–1.62) 25 (21.2) 28 (19.9) 1.20 (0.66–2.18) 31 (19.5)      41 (21.8) 1.12 (0.68–1.83)
≥15 17 (41.5) 13 (27.7) 1.68 (0.78–3.62) 31 (26.3) 34 (24.1) 1.47 (0.86–2.51) 48 (30.2)      47 (25.0) 1.49 (0.97–2.29)
Missing – – 8 (6.8) 6 (4.3) 8 (5.0)      6 (3.2)
p-Value for trend 0.49 0.20 0.10
Italy and Spain, 2007–2013.
aEstimates from multiple logistic regression models including terms for study center, sex, age, education, tobacco smoking, alcohol drinking, body mass index, physical activity, statin 
use, and aspirin use.
bReference category.
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Risk estimates did not meaningfully change when we adjusted the 
models for duration of diabetes. When we mutually adjusted our 
estimates for insulin and metformin, the OR was 0.52 (95% CI 
0.26–1.03) for metformin and 2.00 (95% CI 1.00–3.99) for insu-
lin (data not shown). Using as reference category non-diabetic 
patients besides patients using other antidiabetic drugs, the 
OR was 1.11 (95% CI 0.82–1.53) for any oral medications, 0.98 
(95% CI 0.69–1.40) for metformin, 1.18 (95% CI 0.75–1.86) for 
sulfonylurea derivatives, and 2.04 (95% CI 1.18–3.55) for insulin 
use, with significant trend in risk by increasing duration of insulin 
use (p-value for trend 0.003).
As compared with diabetic patients using other antidiabetic 
medications, the OR of colorectal cancer was 0.69 (95% CI 0.37–1.28) 
for diabetic patients using metformin in monotherapy, 4.29 (95% 
CI 1.61–11.43) for those using sulfonylureas derivatives in mono-
therapy, and 1.70 (95% CI 0.52–5.51) for those using insulin in 
monotherapy; for combinations of therapies, the OR was 0.50 (95% 
CI 0.23–1.07) for diabetic patients using both metformin and sul-
fonylurea derivatives, 1.64 (95% CI 0.67–4.00) for those using both 
metformin and insulin, 0.97 (95% CI 0.19–4.91) for those using both 
sulfonylurea derivatives and insulin, and 3.41 (95% CI 0.56–20.71) 
for those using metformin, sulfonylurea derivatives, and insulin 
(Table S2 in Supplementary Material). Moreover, these estimates 
were consistent when we included in the reference category also 
non-diabetic patients. However, they should be interpreted cau-
tiously since they were based on a small number of patients.
TaBle 4 | Distribution of 109 diabetic colorectal cancer cases and 
135 diabetic controls, with corresponding odds ratios (Ors) and 95% 
confidence intervals (cis), according to use of antidiabetic medications.
antidiabetic  
medications
cases controls Ora (95% ci)
N (%) N (%)
any oral antidiabetic drug
Nob 9 (8.3) 7 (5.2) 1c
Yes 100 (91.7) 128 (94.8) 0.59 (0.18–1.92)
Duration (years)
1 to <5 38 (38.0) 39 (30.5) 0.72 (0.20–2.50)
5 to <10 19 (19.0) 36 (28.1) 0.32 (0.08–1.25)
≥10 34 (34.0) 45 (35.2) 0.50 (0.14–1.78)
Missing 9 (9.0) 8 (6.3)
p-Value for trend 0.21
Metformin
Nod 36 (33.0) 32 (23.7) 1c
Yes 73 (67.0) 103 (76.3) 0.47 (0.24–0.92)
Duration (years)
1 to <5 34 (46.6) 34 (33.0) 0.74 (0.33–1.66)
5 to <10 11 (15.1) 27 (26.2) 0.25 (0.09–0.69)
≥10 20 (27.4) 34 (33.0) 0.36 (0.15–0.85)
Missing 8 (11.0) 8 (7.8)
p-Value for trend 0.005
sulfonylurea derivatives
Nod 68 (62.4) 82 (60.7) 1c
Yes 41 (37.6) 53 (39.3) 1.14 (0.63–2.10)
Duration (years)
1 to <5 14 (34.2) 15 (28.3) 1.60 (0.62–4.09)
5 to <10 7 (17.1) 17 (32.1) 0.59 (0.21–1.64)
≥10 16 (39.0) 19 (35.9) 1.11 (0.47–2.61)
Missing 4 (9.8) 2 (3.8)
p-Value for trend 0.92
insulin
Nod 73 (67.0) 108 (80.0) 1c
Yes 36 (33.0) 27 (20.0) 2.20 (1.12–4.33)
Duration (years)
1 to <5 15 (41.7) 16 (59.3) 1.52 (0.63–3.71)
5 to <10 5 (13.9) 4 (14.8) 1.86 (0.43–8.04)
≥10 14 (38.9) 4 (14.8) 8.18 (2.06–32.50)
Missing 2 (5.6) 3 (11.1)
p-Value for trend 0.002
Spain, 2007–2013.
aEstimates from multiple logistic regression models including terms for study center, 
sex, age, education, tobacco smoking, alcohol drinking, body mass index, physical 
activity, statin use, and aspirin use.
bThis category includes patients using insulin.
cReference category.
dThis category includes also patients using other antidiabetic medications.
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DiscUssiOn
In our study, we find a 20% increased risk of colorectal cancer 
(though of borderline significance) in relation to type 2 diabetes, 
the excess risk being higher for a longer diabetes history and for 
proximal colon cancer. We provided further evidence of a possi-
ble inverse association with metformin and a positive association 
with insulin use, with significant duration–risk relationships.
Previous case–control and cohort studies showed an approxi-
mately 30% excess colorectal cancer risk in patients with diabetes 
as compared with those without diabetes (7–9). We found a 
somewhat lower association in our study which was, however, 
consistent in both the Italian and Spanish study. We found a 
higher risk of colorectal cancer for a history of diabetes of 10 or 
more years, although in the absence of a significant trend in risk. 
Similarly, a meta-analysis of six epidemiological studies reported 
no trend in risk for longer time since diabetes diagnosis (9). 
Furthermore, we found no differences by sex, again in agreement 
with the available evidence (7, 9, 13, 14). The 50% increased risk 
of proximal colon cancer is consistent with findings from previ-
ous studies reporting stronger associations with proximal than 
with distal colon cancer (7, 9, 21).
In the present study, we found a twofold excess risk of colorectal 
cancer in diabetic patients using insulin as compared with users 
of oral antidiabetic medications, with a significant increased risk 
with increasing duration of exposure. A similar increase was 
observed when the reference category also included non-diabetic 
patients and when we considered insulin use as monotherapy. This 
is consistent with the evidence from a meta-analysis − based on 
seven case–control studies and five cohort studies published before 
2014 − which reported an overall RR of colorectal cancer of 1.69 
(95% CI 1.25–2.27) for insulin users (22). However, the results 
of subsequent cohort studies were somewhat inconsistent (23, 
24). Insulin has been shown to increase the risk of colorectal and 
other cancers by influencing the insulin-like growth factor system, 
which, in turn, may stimulate cellular proliferation and inhibit 
apoptosis (25). Insulin injection has also been shown to stimulate 
the growth of colorectal cancer precursors in animal models (26).
Conversely, metformin use was associated to a 50% reduced 
colorectal cancer risk as compared with use of other antidiabetic 
drugs, with a trend of decreasing risk with increasing duration of 
exposure. Consistently, a meta-analysis of five studies conducted 
up to 2011 reported an overall relative risk, RR, of 0.64 (95% CI 
0.54–0.76) for metformin use (16). A weaker inverse association 
was reported in two subsequent meta-analyses that included at 
least nine epidemiological studies, with pooled RRs ranging 
between 0.55 and 0.90 depending on the reference category used 
(15, 17). Such inverse association was found in cohort studies (RR 
0.82, 95% CI 0.71–0.94), but not in case–control studies (RR 1.04, 
95% CI 0.94–1.15) (15). On the contrary, in a subsequent British 
cohort of patients with diabetes, metformin was not associated 
with colorectal cancer mortality (hazard ratio, HR, 1.06, 95% CI 
0.80–1.40) (23). Metformin may reduce colorectal cancer risk by 
activating adenosine monophosphate-activated protein kinase and 
by consequent inhibition of the mammalian target of rapamycin 
(mTOR) (27). Moreover, it can suppress azoxymethane-induced 
formation of colorectal aberrant crypt foci (28, 29). A more wide-
spread use of metformin as a first-line antidiabetic medication and 
its use in less severe cases of diabetes may also explain – at least 
in part – the lower association for history of diabetes observed 
in this study as compared with those conducted in 1980s and 
1990s (10, 12). Moreover, in our study, the inverse relation with 
metformin was weaker when the reference category also included 
non-diabetic patients and in patients using metformin as mono-
therapy, suggesting that metformin may reduce the detrimental 
effect of insulin, rather than having a protective effect itself.
We found no consistent role of sulfonylurea derivatives on 
colorectal cancer risk, the OR being 1.14 when users of sulfonylu-
reas were compared with diabetic patients using other antidiabetic 
medications and 1.18 when the reference category also included 
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non-diabetic patients. Although we found a significant fourfold 
excess risk in diabetic patients using sulfonylurea derivatives as 
monotheraphy, this estimate was based on a small number of 
patients and should be cautiously interpreted. Similarly, a meta-
analysis of three case–control and four cohort studies reported 
a colorectal cancer RR of 1.11 (95% CI 0.97–1.26) in users of 
sulfonylureas as compared with non-users (15). Similarly, in a 
subsequent cohort of patients with diabetes, sulfonylurea was 
not significantly associated with colorectal cancer mortality (HR 
1.14, 95% CI 0.86–1.51) (23).
Limitations of this study are those typical of all case–control 
studies, including selection and information bias. However, in 
both countries, cases and controls came from comparable catch-
ment areas, were interviewed by uniformly trained interviewers, 
and had a satisfactory participation rate for their study design. In 
particular, the high response rate in Italy reflects a traditionally 
high compliance of subjects approached for interview in the Italian 
case–control network; in addition, controls were hospital-based in 
Italy, while population-based in Spain, this explaining the higher 
response rates among controls in Italy as compared with Spain. 
Patients and interviewers were unaware of any hypothesis relating 
diabetes with colorectal cancer, thereby reducing the likelihood 
of potential selection and recall bias. Diagnosis of diabetes was 
self-reported, thus some potential misclassification is possible; 
however, the reliability of information on diabetes provided by 
hospital controls has been shown to be satisfactory (30) and 
the prevalence estimates of diabetes in our control groups were 
consistent with those from national population-based surveys 
(31, 32). Although in the Spanish study we could not distinguish 
between type 1 and type 2 diabetes, we excluded patients with a 
diagnosis of diabetes before age 30, who have been likely affected 
by type 1 diabetes. Another limitation is the lack of information 
on changes in medication type over time – which are frequent 
in diabetic patients – on glycemic level, and on the severity of 
the disease. Indeed, diabetic patients using insulin tend to have 
a more long-lasting and severe disease than non-insulin users. 
Among the strengths of our study is the allowance for major 
confounding factors for colorectal cancer, including body mass 
index and physical activity. Although in our dataset we did not 
have any information on household income and insurance, all 
estimates were adjusted for education, which has been shown to 
be a good proxy of socioeconomic status. Another strength of our 
study is that we were able to analyze the relation with duration of 
diabetes and use of various antidiabetic medications, exploring 
long-term exposures (i.e., >10 years), which have been examined 
in a limited number of studies.
Our study confirmed a positive association between diabetes 
and colorectal cancer, mainly proximal colon cancer. Among 
antidiabetic medications, it indicates a favorable effect for met-
formin use and a detrimental effect for insulin use, suggesting a 
need for enhanced screening measures for colorectal cancer in 
insulin-treated patients. It is, however, not easy to disentangle 
the effect of each antidiabetic medication since diabetic patients 
often use more than one medication, especially for more severe 
disease. Thus, it is difficult to establish whether these associations 
are causal or influenced by different severity of the disease and 
confounding.
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